Faeth Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Faeth Therapeutics, Inc. (FTH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $150.58 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $150.58, a 18722.50% increase year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.80.
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $9.84.
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $133.22, a 1876.56% increase from fiscal 2024.
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $6.74, a 45.60% decline from fiscal 2023.
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $12.39, a 13.78% decline from fiscal 2022.
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $14.37.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $150.58 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $150.58 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $133.22 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $117.87 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $130.25 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $0.80 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $6.74 10-K · filed 2025-03-28 | |||
| 2024-09-30 | $11.97 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $14.36 10-Q · filed 2024-08-06 | |||
| 2023-12-31 | $12.39 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $8.73 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $8.77 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $9.84 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $14.37 10-K · filed 2023-03-29 | |||
| 2022-09-30 | $14.40 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $14.12 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |